LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

LLY

747.7

-1.07%↓

JNJ

148.51

-3.47%↓

UNH

310.52

-17.94%↓

ABBV

187.96

-1.03%↓

ABT

129.08

-2.23%↓

Search

Theravance Biopharma Inc

Închisă

8.82 -1.56

Rezumat

Modificarea prețului

24h

Curent

Minim

8.73

Maxim

9.01

Indicatori cheie

By Trading Economics

Venit

-2.8M

-16M

Vânzări

1.9M

19M

EPS

-0.05

Marjă de profit

-82.798

Angajați

97

EBITDA

1.7M

-6.9M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+69.82% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

62M

515M

Deschiderea anterioară

10.38

Închiderea anterioară

8.82

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Theravance Biopharma Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 mai 2025, 22:34 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 mai 2025, 22:43 UTC

Câștiguri

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 mai 2025, 22:08 UTC

Achiziții, Fuziuni, Preluări

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 mai 2025, 22:07 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Australia Retail Electricity Business to AGL

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 mai 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 mai 2025, 22:05 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 mai 2025, 22:04 UTC

Achiziții, Fuziuni, Preluări

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 mai 2025, 21:15 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Rev $2.65B >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q Net $115M >CSU.T

12 mai 2025, 21:01 UTC

Câștiguri

Constellation Software 1Q EPS $5.44 >CSU.T

12 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Basic Materials Roundup: Market Talk

12 mai 2025, 20:44 UTC

Top știri

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 mai 2025, 20:31 UTC

Top știri

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 mai 2025, 20:24 UTC

Câștiguri

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 mai 2025, 20:24 UTC

Top știri

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 mai 2025, 20:22 UTC

Achiziții, Fuziuni, Preluări

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 mai 2025, 20:15 UTC

Câștiguri

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 mai 2025, 20:10 UTC

Câștiguri

Blink Charging 1Q Rev $20.8M >BLNK

Comparație

Modificare preț

Theravance Biopharma Inc Așteptări

Obiectiv de preț

By TipRanks

69.82% sus

Prognoză pe 12 luni

Medie 15.25 USD  69.82%

Maxim 24 USD

Minim 10 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTheravance Biopharma Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

9.77 / 10.39Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.